Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Glioblastoma × trans-sodium crocetinate × Clear all

Phase

Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Temozolomide 35 Radiotherapy 16 Lomustine 10 Bevacizumab 10 Carmustine 7 Radiation 6 Procarbazine 4 Surgical Procedures, Operative 3 Magnetic Resonance Spectroscopy 3 pembrolizumab 2 Tf-CRM107 2 Radiotherapy, Intensity-Modulated 2 Drug Therapy 2 Dihematoporphyrin Ether 2 DNA Methylation 2 Carboplatin 2 trans-sodium crocetinate 1 tofacitinib 1 sargramostim 1 rindopepimut 1 niraparib 1 marizomib 1 edotecarin 1 depatuxizumab mafodotin 1 contrast agent BR1 1 cediranib 1 carmustine, poliferprosan 20 drug combination 1 Vincristine 1 Valproic Acid 1 TVB-2640 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03393000 2021-07-22

INTACT

Diffusion Pharmaceuticals Inc

Phase 3 Terminated

19 enrolled 8 charts

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡